<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184050</url>
  </required_header>
  <id_info>
    <org_study_id>HPN217-3001</org_study_id>
    <nct_id>NCT04184050</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM</brief_title>
  <official_title>A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harpoon Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harpoon Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, Phase 1/2 study of HPN217 as monotherapy to assess the safety, tolerability
      and PK in patients with relapsed/ refractory multiple myeloma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">June 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Adverse Events by CTCAE v5.0 of HPN217</measure>
    <time_frame>4 years</time_frame>
    <description>Assess safety and tolerability at increasing dose levels of HPN217 in successive cohorts of patients with RRMM by way of adverse events (CTCAE v5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine MTD/ RP2D</measure>
    <time_frame>2 years</time_frame>
    <description>Estimate the maximum tolerated dose (MTD) or select the recommended Phase 2 dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize Pharmacokinetics of Serum levels of HPN217</measure>
    <time_frame>2 years</time_frame>
    <description>Characterize single dose and multiple dose pharmacokinetics (PK) of HPN217 following intravenous (IV) administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine Efficacy by way of Disease Assessment using IMWG Response Criteria</measure>
    <time_frame>4 years</time_frame>
    <description>Evaluate preliminary efficacy of HPN217 by way of Disease Assessment using IMWG Response Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine Immunogenicity by way of Anti-drug Antibodies</measure>
    <time_frame>4 years</time_frame>
    <description>Evaluate immunogenicity of HPN217 by way of serum anti-drug antibodies being measured at different time points of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Multiple Myeloma in Relapse</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Multiple Myeloma of Bone</condition>
  <condition>Multiple Myeloma With Failed Remission</condition>
  <arm_group>
    <arm_group_label>Part 1 (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPN217 is IV administered 1x weekly for about 1 hour. Doses will vary between cohorts as MTD is being determine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPN217 is IV administered 1x weekly for about 1 hour. Doses will be determined from Part 1 (dose escalation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPN217</intervention_name>
    <description>HPN217 is a tri-specific recombinant protein construct (Tri-specific T Cell Activating Construct [TriTAC®]) containing 3 humanized antibody derived binding domains</description>
    <arm_group_label>Part 1 (Dose Escalation)</arm_group_label>
    <arm_group_label>Part 2 (Dose Expansion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          1. Received at least 3 prior therapies (including proteasome inhibitor, immune modulatory
             drug, and an anti-CD38 antibody; patients should not be a candidate for or be
             intolerant of all established therapies known to provide clinical benefit in multiple
             myeloma).

          2. Measurable disease defined as at least one of the following:

               1. Serum M-protein ≥0.5 g/dL

               2. Urine M-protein ≥200 mg/24 hours

               3. Serum free light chain (FLC) assay: Involved FLC level ≥10 mg/dL (≥100 mg/L)

          3. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

          4. Adequate hematologic status, including:

               1. Absolute neutrophil count (ANC) ≥1000 cells/μL

               2. Platelet count ≥50,000/μL (without transfusions)

               3. Hemoglobin ≥8 g/dL

          5. Adequate renal function, including:

             a. Calculated creatinine clearance ≥30 mL/min using the formula of Cockcroft and Gault

          6. Adequate hepatic function, including

               1. Total bilirubin ≤1.5 × upper limit of normal (ULN), regardless of direct
                  bilirubin

               2. AST and ALT ≤3.0 × ULN (≤5.0× ULN if due to myeloma involvement)

               3. Alkaline phosphatase ≤3× ULN (≤5.0× ULN if due to myeloma involvement)

        Major Exclusion Criteria:

          1. Prior exposure to BCMA-targeting agents (Part 2 only)

          2. Concurrent treatment with anti-tumor necrosis factor alpha therapies, systemic
             corticosteroids (prednisone dose &gt;10 mg per day or equivalent), or other immune
             suppressive drugs within the 2 weeks prior to Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Bismarck, RN, MSN</last_name>
      <phone>480-256-5463</phone>
      <email>Lisa.Bismarck@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Sumit Madan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Vick, MHA</last_name>
      <phone>720-754-4890</phone>
      <email>James.Vick@SarahCannon.com</email>
    </contact>
    <investigator>
      <last_name>Henning Schade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OHSU</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Seybold</last_name>
      <phone>503-494-9298</phone>
      <email>seyboldc@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Eva Medvedova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystle Pagarian</last_name>
      <phone>206-386-2098</phone>
      <email>krystle.pagarigan@swedish.org</email>
    </contact>
    <investigator>
      <last_name>William Bensigner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

